The Asian Pacific Association for the Study of the Liver
Single Topic Conference in Nagasaki
“Prevention of HCC development”

Program & Abstracts

April 10-12, 2017
Hotel Okura JR Huis Ten Bosch, Nagasaki, Japan

Hiroshi Yatsuhashi M.D.
Director General, Clinical Research Center,
National Hospital Organization (NHO) Nagasaki Medical Center
Professor, Department of Hepatology,
Nagasaki University Graduate School of Biomedical Sciences

Supported by JSII
APASL Single Topic Conference in Nagasaki
“Prevention of HCC development”

April 10-12, 2017
Hotel Okura JR Huis Ten Bosch

Table of Contents
Welcome Message 3
Committees 4
Conference Information 6
Transportation 7
Venue 8
Instruction for Oral Presentation 9
Information for Chairs 9
Instruction for Poster Presentation 10
Awards / Contact 11
Sponsors and Support Organization 12
Program at a Glance 14
Scientific Program 18
Abstracts: General Sessions 39
Abstracts: Sponsored Seminars 63
Abstract: Special Lecture 87
Abstracts: Oral Free Papers 89
Abstracts: Poster Free Papers 107
Dear Colleagues,

On behalf of the Organizing Committee, it gives us great pleasure to invite you to Asian Pacific Association for the Study of the Liver Single Topic Conference (APASL STC), which will be held on April 10-12, 2017 in Nagasaki, Japan. We are delighted to welcome you to the beautiful, exotic city of Nagasaki in Kyushu Island of Japan.

Under the theme of “Prevention of HCC Development”, the conference program will present high-quality content based on up-to-date information and cutting edge lectures by eminent researchers, to reconfirm the achievement of better basic and clinical practice in the field of Prevention of HCC Development. Currently when the hepatitis virus has been eliminated and control has become possible, the most important thing is to further strengthen the suppression of HCC occurrence, and by justification of HCC risk and application in practical clinics, prediction of carcinogenesis. I hope that presenting the results of basic research and clinical research on the prevention of HCC development in NAGASAKI-STC conference and considering future liver disease research will be milestones in this field.

In NAGASAKI-STC, the scientific program will consist of invited lectures, educational symposia, and free papers on significant developments on the theme of Prevention and Management of HCC Development. The program will also provide the latest information and fresh ideas for hepatologists.

Approximately 1000 delegates of experts from all over the world are expected to attend this conference. We are sure that this will provide an excellent opportunity for those of us in the Asian Pacific region to share the latest views, values, experience and practice, and greatly contribute to the progress of Prevention of HCC Development.

Conference attendees will be able to enjoy fantastic Nagasaki in the season when tulips and other flowers are in full bloom in a popular park situated just across the street from the conference venue.

With warmest regards,

April 2017

Hiroshi Yatsuhashi M.D.
President, APASL Single Topic Conference in Nagasaki
Director General, Clinical Research Center,
National Hospital Organization (NHO) Nagasaki Medical Center
Professor, Department of Hepatology,
Nagasaki University Graduate School of Biomedical Sciences
Committees

Scientific Committee

Dr. Yuko Akazawa (Japan)  Dr. Yasuhiro Asahina (Japan)  Dr. Oidov Baatarkhuu (Mongolia)
Dr. Kazuaki Chayama (Japan)  Dr. Wan-Long Chuang (Taiwan)  Dr. A. Kadir Dokmeci (Turkey)
Dr. Nobuyuki Enomoto (Japan)  Dr. Kwang-Hyub Han (Korea)  Dr. Etsuko Hashimoto (Japan)
Dr. Yoichi Hiasa (Japan)  Dr. Keisuke Hino (Japan)  Dr. Jinlin Hou (China)
Dr. Takafumi Ichida (Japan)  Dr. Akio Ido (Japan)  Dr. Namiki Izumi (Japan)
Dr. Wasim Jafri (Pakistan)  Dr. Masayoshi Kage (Japan)  Dr. Tatsuo Kanda (Japan)
Dr. Shuichi Kaneko (Japan)  Dr. Tatsuya Kanto (Japan)  Dr. Jia-Horng Kao (Taiwan)
Dr. Norifumi Kawada (Japan)  Dr. Kazuhiko Koike (Japan)  Dr. Masatoshi Kudo (Japan)
Dr. Takashi Kumada (Japan)  Dr. George Lau (China)  Dr. Laurentius A. Lesmana (Indonesia)
Dr. Tsutomu Masaki (Japan)  Dr. Yasushi Matsuzaki (Japan)  Dr. Masashi Mizokami (Japan)
Dr. Eishiro Mizukoshi (Japan)  Dr. Satoshi Mochida (Japan)  Dr. Makoto Nakamuta (Japan)
Dr. Hiroyuki Nakanishi (Japan)  Dr. Shuhei Nishiguchi (Japan)  Dr. Jun Qi Niu (China)
Dr. Hideyuki Nomura (Japan)  Dr. Shuntaro Obi (Japan)  Dr. Sadahisa Ogasawara (Japan)
Dr. Masao Omata (Japan)  Dr. Isao Sakaida (Japan)  Dr. Naoya Sakamoto (Japan)
Dr. Shotaro Sakisaka (Japan)  Dr. Shiv K. Sarin (India)  Dr. Yutaka Sasaki (Japan)
Dr. Barjesh C. Sharma (India)  Dr. Shinji Shimoda (Japan)  Dr. Koichi Shiraishi (Japan)
Dr. Jose Sollano (Philippines)  Dr. Fumitaka Suzuki (Japan)  Dr. Tetsuo Takehara (Japan)
Dr. Atsushi Tanaka (Japan)  Dr. Eiji Tanaka (Japan)  Dr. Junko Tanaka (Japan)
Dr. Yasuhito Tanaka (Japan)  Dr. Takui Torimura (Japan)  Dr. Yoshiyuki Ueno (Japan)
Dr. Takaji Wakita (Japan)  Dr. Osamu Yokosuka (Japan)  Dr. Seung Kew Yoon (Korea)
Dr. Hitoshi Yoshiji (Japan)  Dr. Kentaro Yoshioka (Japan)  Dr. Hiroshi Yotsuyanagi (Japan)
Dr. Ming Lung Yu (Taiwan)  Dr. Xinxin Zhang (China)  

In alphabetical order

Local Committee

President
Dr. Hiroshi Yatsuhashi

Vice-President
Dr. Shuichiro Shiina

Treasurer
Dr. Kazuhiko Nakao

Vice-Treasurer
Dr. Naoya Kato

Secretary General
Dr. Atsumasa Komori
APASL Steering Committee

Chair of Steering Committee Dr. Shiv K. Sarin (India)
President Dr. Barjesh C. Sharma (India)
Immediate Past President Dr. Jinlin Hou (China)
President Elect Dr. Diana A. Payawal (Philippines)
Secretary General-cum-Treasurer Dr. Lai Wei (China)
Past Presidents Dr. Laurentius A. Lesmana (Indonesia)
Dr. Jose Sollano (Philippines)
Dr. Masao Omata (Japan)
Dr. Dong Jin Suh (Korea)
Dr. George Lau (China)
Dr. Ji-Dong Jia (China)
Dr. Teerha Piratvisuth (Thailand)
Dr. Jia-Horng Kao (Taiwan)
Dr. Darrell Crawford (Australia)
Dr. A. Kadir Dokmeci (Turkey)
Dr. Osamu Yokosuka (Japan)

APASL Executive Council

President Dr. Barjesh C. Sharma (India)
Immediate Past President Dr. Jinlin Hou (China)
President Elect Dr. Diana A. Payawal (Philippines)
Secretary General-cum-Treasurer Dr. Lai Wei (China)
Assistant Secretary Dr. Manoj K. Sharma (India)
Executive Council Dr. Shahab Abid (Pakistan)
Dr. Deepak Amarapurkar (India)
Dr. Ian Homer Y. Cua (Philippines)
Dr. Ghazinyan Hasmik (Armenia)
Dr. Changmin Kim (Korea)
Dr. Han-Chieh Lin (Taiwan)
Dr. Rosmawati Mohamed (Malaysia)
Dr. David H. Muljono (Indonesia)
Dr. Necati Ormeci (Turkey)
Dr. Shuichiro Shiina (Japan)
Dr. Tawesak Tanwandee (Thailand)
Dr. Alexander Thompson (Australia)
Dr. Fu-Sheng Wang (China)
Conference Information

Registration Fee and Category

<table>
<thead>
<tr>
<th>Category</th>
<th>Before Feb. 14 (Tue) 2017 (Early Bird)</th>
<th>From Feb. 15 (Wed) 2017 Before Mar. 31 (Fri) 2017</th>
<th>On Site</th>
</tr>
</thead>
<tbody>
<tr>
<td>APASL Member*</td>
<td>JPY15,000</td>
<td>JPY20,000</td>
<td>JPY25,000</td>
</tr>
<tr>
<td>Non Member</td>
<td>JPY20,000</td>
<td>JPY25,000</td>
<td>JPY30,000</td>
</tr>
<tr>
<td>Trainee / Resident**</td>
<td>JPY10,000</td>
<td>JPY15,000</td>
<td>JPY20,000</td>
</tr>
<tr>
<td>Presenting Author</td>
<td>JPY15,000</td>
<td>JPY20,000</td>
<td>JPY25,000</td>
</tr>
<tr>
<td>Accompanying Person</td>
<td>JPY5,000</td>
<td>JPY5,000</td>
<td>JPY5,000</td>
</tr>
</tbody>
</table>

JPY=Japanese Yen
*APASL Members who have paid 2017 Membership fee can apply for above discounted registration fee.
**Proof of status is required.

Registration Fee and Items included

APASL Member, Non Member, Trainee/Resident, Presenting Author:
- Attendance to all scientific sessions
- Entrance to exhibition area
- Congress bag and printed materials
- Coffee breaks to be served during the scientific program
- Welcome Reception on April 10 (Monday)

Accompanying Person:
- Entrance to exhibition area
- Welcome Reception on April 10 (Monday)

Registration Hours

<table>
<thead>
<tr>
<th>Date</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>April 10 (Monday)</td>
<td>8:00-17:00</td>
</tr>
<tr>
<td>April 11 (Tuesday)</td>
<td>7:30-17:30</td>
</tr>
<tr>
<td>April 12 (Wednesday)</td>
<td>7:30-10:00</td>
</tr>
</tbody>
</table>

Exhibition Hours

<table>
<thead>
<tr>
<th>Date</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>April 10 (Monday)</td>
<td>12:00-18:00</td>
</tr>
<tr>
<td>April 11 (Tuesday)</td>
<td>8:00-18:00</td>
</tr>
<tr>
<td>April 12 (Wednesday)</td>
<td>8:00-10:30</td>
</tr>
</tbody>
</table>

Social Event

Welcome Reception: Date and Time: April 10 (Monday) 19:00-21:00
Place: Hall “OHTORI”, 1st Floor, Hotel Okura JR Huis Ten Bosch
*Welcome Reception is included in Registration Fee.
Transportation

Conference Venue: **Hotel Okura JR Huis Ten Bosch**
Address: 10, Huis Ten Bosch-cho, Sasebo-city, Nagasaki, 859-3296, Japan
Tel: +81-956-58-7111

From Nagasaki Airport
50 minutes by express bus from Nagasaki Airport to the venue.
50 minutes by express cruise from Nagasaki Airport to the venue.
3 minutes walk from JR Huis Ten Bosch Station to the venue.

From Fukuoka Airport
5 minutes from Fukuoka Airport to JR Hakata Station by subway.
100 minutes from JR Hakata Station to JR Huis Ten Bosch Station.
3 minutes walk from JR Huis Ten Bosch Station to the venue.

From JR Nagasaki Station
90 minutes by train from JR Nagasaki Station to JR Huis Ten Bosch Station.
3 minutes walk from JR Huis Ten Bosch Station to the venue.

By car
15 minutes drive from Sasebo Daito Interchange Nagasaki Expressway to the venue.
Venue

Hotel Okura JR Huis Ten Bosch
Oral Session: Room 1 “OHTORI” A, 1st Floor
Room 2 “OHTORI” B, 1st Floor
Registration Desk: Foyer, in front of “OHTORI”, 1st Floor
Cloak: Foyer, 1st Floor
PC Preview Desk: Foyer, in front of “OHTORI”, 1st Floor
Poster Session: Room 3 “ASUKA”, 1st Floor (P-001～P-051)
Room 4 “PEARL”, 12th Floor (P-052～P-120)
Exhibition: Foyer, in front of “OHTORI”, 1st Floor
Secretariat Room: “SHIRASAGI”, 2nd Floor
Speaker’s Ready Room: “OSHIDORI” “CHIDORI”, 2nd Floor
Welcome Reception: “OHTORI”, 1st Floor
Instruction for Oral Presentation

*All Oral Presentation is performed with PowerPoint data on Windows PC.
*Please complete your PC registration until 30 minutes ahead of your presentation time.
*PC Data Registration Desk is located on the Foyer, 1st Floor, Hotel Okura JR Huis Ten Bosch. The open hours is as follows.

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>April 10 (Mon)</td>
<td>8:30-18:00</td>
</tr>
<tr>
<td>April 11 (Tue)</td>
<td>7:30-18:00</td>
</tr>
<tr>
<td>April 12 (Wed)</td>
<td>7:30-10:00</td>
</tr>
</tbody>
</table>

*Please operate your PPT data by yourself at the podium.
*The projector’s screen resolution is set at 4:3 XGA. Please make your PPT data the necessary preparation if needed. (16:9 XGA is also projectable with a size smaller, black flamed at the top and bottom)

<If you bring your own PC>
*Windows PC will be set at the conference room for your presentation.
*Please make sure that your PC has D-Sub 15 pin mini terminal for monitor output. (Some compact PC needs another connector. In case of that, please carry your own connector.)
*Macintosh and Key Note are acceptable only if you will bring your own PC. (Please carry your own connector.)
*Please bring battery adapter to avoid battery off. Because sometimes screen saver or power saving system could be a reason of battery off, please set your PC appropriately.

<If you bring your data by portable media>
*To avoid garbled characters, please use standard font which is originally installed by OS.
*Please put your name on your data file.
*Please bring your data by USB memory stick, CDR, or DVDR (Disk at Once).
*Backup data by another media should be kept by presenter.
*If you bring your movies by data file, please prepare the file which can be played by standard Windows Media Player.

Information for Chairs

Session Chairs are required to come to the next chair’s seat until 10 minutes before their sessions.
Instruction for Poster Presentation

* A panel width 90cm×length 210cm will be provided for each poster as following sample.
* Poster number will be prepared by secretariat.
* Title and author’s name are required to be prepared by each presenter.
* Pins for display will be provided at each poster panel.
* Place: Poster No. P-001～P-051: “ASUKA”, 1st Floor, Hotel Okura JR Huis Ten Bosch
  Poster No. P-052～P-120: “PEARL”, 12th Floor, Hotel Okura JR Huis Ten Bosch

* Schedule:
  Poster Attachment: 8:30-12:00 on April 10 (Monday)
  Poster Presentation & Discussion: 17:00-18:30 on April 10 (Monday)
    17:00-17:30 (30 min.) Presentation time for odd number of Poster No.
    17:30-18:00 (30 min.) Presentation time for even number of Poster No.
    18:00-18:30 (30 min.) Free discussion time of all Posters
  Awarding Ceremony: at Welcome Reception during 19:00-21:00 on April 10 (Monday)
  Poster Removal: 15:00-16:00 on April 11 (Tuesday)
Awards

Excellent papers will be awarded as “Presidential Award” or “Young Investigator Award”. Awarding Ceremony will be held at Welcome Reception during 19:00-21:00 on April 10 (Monday).

Presidential Award

“APASL STC Nagasaki Presidential Award” will be awarded to whom performed the most excellent presentation in APASL STC Nagasaki to encourage to further their research and progress.

Young Investigator Award (Under 40 years old)

The purpose of the “APASL STC Nagasaki Young Investigator Award” is to praise outstanding examples of excellence amongst those involved in research training in the early stages of their career.

Contact

APASL STC Nagasaki Scientific Secretariat
National Hospital Organization (NHO) Nagasaki Medical Center
Kubara 2-1001-1, Omura, Nagasaki, 856-8562, Japan

APASL STC Nagasaki Congress Secretariat
c/o Academia Support Japan, 8F Nittochi Nishi-Shinjuku Bldg.
6-10-1, Nishi-Shinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan
Email: info@apaslstc2017nagasaki.org
Tel: +81-3-6380-0102 Fax: +81-3-6380-0103

APASL Central Office (APASL Secretariat-Tokyo)
Asian Pacific Association for the Study of the Liver (APASL)
1-24-7-920, Shinjuku, Shinjuku-ku, Tokyo, 160-0022, Japan
Email: apasl_secretariat@apasl.info
Tel: +81-3-5312-7686 Fax: +81-3-5312-7687
Sponsors and Support Organization

The Organizing Committee of the APASL Single Topic Conference Nagasaki would like to express sincere thanks to the following sponsors and organization for supporting this conference.

Sponsors

Abbott Japan Co., Ltd.
AbbVie GK

Alexion Pharma
ASKA Pharmaceutical Co., Ltd.

Astellas Pharma Inc.
Bayer Yakuhin, Ltd.

Bristol-Myers Squibb K.K
CHUGAI PHARMACEUTICAL CO., LTD.

Daiichi Sankyo Co., Ltd.
Eiken Chemical Co., LTD.

Eisai Co., Ltd.
Eli Lilly Japan K.K.
LSI Medience Corp.
LSI Medience Corporation

GE Healthcare

GlaxoSmithKline K.K.

Fujirebio Inc.

Gilead Sciences K.K.

Janssen Pharmaceutical K.K.

MSD K.K.

Otsuka Pharmaceutical Co., Ltd.

PhoenixBio Co., Ltd.

Roche Diagnostics K.K.

Sumitomo Dainippon Pharma Co., Ltd.

SYSMEX CORPORATION

Support Organization
The Japan Society of Hepatology

In alphabetical order.
# Program at a Glance

## April 10 (Monday) 2017

<table>
<thead>
<tr>
<th>Room1  “OHTORI A”</th>
<th>Room2  “OHTORI B”</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>9:00</strong></td>
<td><strong>9:50</strong></td>
</tr>
<tr>
<td>Registration</td>
<td>Oral Free Papers: PBC</td>
</tr>
<tr>
<td><strong>9:20</strong></td>
<td><strong>9:50-10:30</strong></td>
</tr>
<tr>
<td>9:20-9:30 Opening Ceremony</td>
<td>Oral Free Papers: PBC</td>
</tr>
<tr>
<td><strong>9:30-11:00</strong></td>
<td><strong>9:50-10:30</strong></td>
</tr>
<tr>
<td>Session 1 Epidemiology and Risk Factors for HCC</td>
<td>Oral Free Papers: PBC</td>
</tr>
<tr>
<td>Chairs:</td>
<td>Chair: Dr. Shinji Shimoda</td>
</tr>
<tr>
<td>1. Dr. A. Kadir Dokmeci</td>
<td>0-000, 0-001, 0-002, 0-003</td>
</tr>
<tr>
<td>2. Dr. Osamu Yokosuka</td>
<td><strong>10:30-11:20</strong> Oral Free Papers: Fibrosis</td>
</tr>
<tr>
<td>Presenters</td>
<td>Chair: Dr. Norifumi Kawada</td>
</tr>
<tr>
<td>1. Dr. Yasuhiro Asahina</td>
<td>0-004, 0-005, 0-006, 0-007, 0-008</td>
</tr>
<tr>
<td>2. Dr. Yoshiyuki Ueno</td>
<td><strong>11:00-13:00</strong> Luncheon Seminar 1 (Sponsored by Gilead Sciences K.K.)</td>
</tr>
<tr>
<td>3. Dr. Tatsuya Kanto</td>
<td><strong>13:00-13:50</strong> Oral Free Papers: HBV</td>
</tr>
<tr>
<td><strong>11:30</strong></td>
<td><strong>13:10-13:50</strong></td>
</tr>
<tr>
<td>Luncheon Seminar 1 (Sponsored by Gilead Sciences K.K.)</td>
<td>Oral Free Papers: HBV</td>
</tr>
<tr>
<td>Chair: Dr. Takaumi Ichida</td>
<td>Chair: Dr. Yasuhiro Tanaka</td>
</tr>
<tr>
<td>Presenters</td>
<td>0-009, 0-010, 0-011, 0-012</td>
</tr>
<tr>
<td>1. Dr. Tetsuo Takehara</td>
<td><strong>13:50-14:30</strong> Oral Free Papers: Pathology</td>
</tr>
<tr>
<td>2. Dr. Mei-Hsuan Lee</td>
<td>Chair: Dr. Masayoshi Kage</td>
</tr>
<tr>
<td>3. Dr. Edward Gane</td>
<td>0-013, 0-014, 0-015, 0-016</td>
</tr>
<tr>
<td><strong>13:00</strong></td>
<td><strong>14:00-15:00</strong></td>
</tr>
<tr>
<td>Educational Symposium (Sponsored by Alexion Pharma)</td>
<td>Oral Free Papers: HCC Clinical 1</td>
</tr>
<tr>
<td>Chair: Dr. Akio Ido</td>
<td>Chair: Dr. Kelsuke Hino</td>
</tr>
<tr>
<td>Presenters</td>
<td>0-017, 0-018, 0-019, 0-020, 0-021</td>
</tr>
<tr>
<td>1. Dr. Yoshikatsu Eto</td>
<td><strong>14:40-15:30</strong> Oral Free Papers: HCC Clinical 1</td>
</tr>
<tr>
<td>2. Dr. Koichi Shiraishi</td>
<td><strong>15:30-16:20</strong> Oral Free Papers: HCC Clinical 2</td>
</tr>
<tr>
<td>3. Dr. Masatsune Ogura</td>
<td>Chair: Dr. Yutaka Sasaki</td>
</tr>
<tr>
<td><strong>14:40</strong></td>
<td><strong>15:30-16:20</strong></td>
</tr>
<tr>
<td>14:40-15:00 Session 2 HCC-1</td>
<td>Oral Free Papers: HCC Clinical 2</td>
</tr>
<tr>
<td>Chair: Dr. Laurentius Lesmana</td>
<td>Chair: Dr. Tsutomu Masaki</td>
</tr>
<tr>
<td>Presenters</td>
<td>Chair: Dr. Tsutomu Masaki</td>
</tr>
<tr>
<td>1. Dr. Shulchi Kaneko</td>
<td>0-027, 0-028, 0-029, 0-030</td>
</tr>
<tr>
<td>2. Dr. Masao Omata</td>
<td><strong>16:20-17:00</strong> Oral Free Papers: HCC Basic</td>
</tr>
<tr>
<td><strong>15:50</strong></td>
<td><strong>16:20-17:00</strong></td>
</tr>
<tr>
<td>15:50-16:00 Evening Seminar 1 (Sponsored by AbbVie GK)</td>
<td>Oral Free Papers: HCC Basic</td>
</tr>
<tr>
<td>Chair: Dr. Kazuhiko Nakao</td>
<td>Chair: Dr. Tsutomu Masaki</td>
</tr>
<tr>
<td>Presenters</td>
<td>Chair: Dr. Tsutomu Masaki</td>
</tr>
<tr>
<td>1. Dr. Yoichi Hiasa</td>
<td><strong>16:20-17:00</strong> Oral Free Papers: HCC Basic</td>
</tr>
<tr>
<td>2. Dr. Satoshi Mochida</td>
<td>Chair: Dr. Tsutomu Masaki</td>
</tr>
<tr>
<td><strong>17:00</strong></td>
<td><strong>19:00-21:00</strong></td>
</tr>
<tr>
<td><strong>18:00-19:00</strong> Welcome Reception</td>
<td><strong>19:00-21:00</strong> Welcome Reception</td>
</tr>
<tr>
<td><strong>21:00</strong></td>
<td><strong>21:00</strong></td>
</tr>
</tbody>
</table>
### April 11 (Tuesday) 2017

<table>
<thead>
<tr>
<th>Time</th>
<th>Room 1 “OHTORI A”</th>
<th>Room 2 “OHTORI B”</th>
</tr>
</thead>
</table>
| 8:00 | 8:00-9:00 Morning Seminar 1  
(Sponsored by Eisai Co., Ltd.)  
Chair: Dr. Masao Omata  
Presenters  
①Dr. Sadahisa Ogasawara  
②Dr. Shuntaro Obi | 8:00-9:00 Morning Seminar 2  
(Sponsored by Roche Diagnostics K.K.)  
Chair: Dr. Takashi Kumada  
Presenters  
①Dr. Junko Tanaka  
②Dr. Yasuhiro Tanaka |
| 9:00 |  
9:10-10:40 Session 3 HCV  
Chair: Dr. Wan-Long Chuang  
Presenters  
①Dr. Nobuyuki Enomoto  
②Dr. Tatsuo Kanda  
③Dr. Hiroshi Yatsuhashi | 9:00-10:30 Luncheon Seminar 2  
(Sponsored by MSD K.K.)  
Chair: Dr. Kazuhiko Koike  
Presenters  
①Dr. Naoya Sakamoto  
②Dr. Kazuaki Chayama |
| 10:40 |  
10:50-11:50 Session 4 HBV  
Chair: Dr. Jose Sollano  
Presenters  
①Dr. Kwang-Hyub Han  
②Dr. Jia-Horng Kao | 12:00-13:00 Luncheon Seminar 3  
(Sponsored by Otsuka Pharmaceutical Co., Ltd.)  
Chair: Dr. Namiki Izumi  
Presenters  
①Dr. Hiroyuki Nakanishi  
②Dr. Isao Sakaida |
| 11:50 |  
12:00-13:00 Luncheon Seminar 2  
(Sponsored by MSD K.K.)  
Chair: Dr. Kazuhiko Koike  
Presenters  
①Dr. Naoya Sakamoto  
②Dr. Kazuaki Chayama | 13:15-15:15 Session 6 LC (NASH)  
Chair: Dr. Shotaro Sakisaka  
②Dr. Barjesh C. Sharma  
Presenters  
①Dr. Norifumi Kawada  
②Dr. Keisuke Hino  
③Dr. Hitoshi Yoshiji  
④Dr. Etsuko Hashimoto |
| 13:15 |  
13:15-15:45 Session 5 HCC-2  
Chair: ①Dr. Wasim Jafari  
②Dr. George Lau  
Presenters  
①Dr. Naoya Kato  
②Dr. Masatoshi Kudo  
③Dr. Shuichiro Shina  
④Dr. Takaji Torimura  
⑤Dr. Sadahisa Ogasawara | 15:15-16:00 Special Lecture HCC and Gene  
Chair: Dr. Hiroshi Yatsuhashi  
Presenter  
①Dr. Seung Kew Yoon |
| 15:45 |  
16:00-17:30 Evening Seminar 2  
(Sponsored by Sysmex Corporation)  
Chair: ①Dr. Masashi Mizokami  
②Dr. Seung Kew Yoon  
Presenters  
①Dr. Xinxin Zhang  
②Dr. Jun-Qi Niu  
③Dr. Ming Lung Yu  
④Dr. Yasuhiro Asahina  
⑤Dr. Kazumi Yamasaki | 15:50-16:30 Special Lecture HCC and Gene  
Chair: Dr. Hiroshi Yatsuhashi  
Presenter  
①Dr. Seung Kew Yoon |
| 19:00 |  
19:00-21:00  
Faculty Dinner |
<table>
<thead>
<tr>
<th>Time</th>
<th>Room 1 “OHTORI A”</th>
<th>Room 2 “OHTORI B”</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00</td>
<td>Morning Seminar 3</td>
<td>Morning Seminar 4</td>
</tr>
<tr>
<td>9:00</td>
<td>Session 7 Lipid</td>
<td>Session 8 PBC</td>
</tr>
<tr>
<td>10:20</td>
<td>Closing Ceremony</td>
<td></td>
</tr>
</tbody>
</table>

**Room 1 “OHTORI A”**
- **Chair:** Dr. Kentaro Yoshioka
- **Presenters:**
  1. Dr. Fumitaka Suzuki
  2. Dr. Hiroshi Yotsuyanagi

**Room 2 “OHTORI B”**
- **Chair:** Dr. Hiroshi Yatsuhashi
- **Presenters:**
  1. Dr. Kazuhiro Tanabe
  2. Dr. Makoto Nakamura
  3. Dr. Shinji Shimoda
  4. Dr. Atsushi Tanaka

**Session 7 Lipid and HCV Lipid and HCC**
- **Chairs:**
  1. Dr. Oldov Baatarkhhuu
  2. Dr. Naoya Kato

**Session 8 PBC**
- **Chair:** Dr. Yasushi Matsuzaki
# Scientific Program

## General Session

### April 10 (Monday) 2017

**Room 1 (1st Floor "OHTORI A")**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:20〜9:30</td>
<td>Opening Ceremony</td>
</tr>
<tr>
<td></td>
<td>Hiroshi Yatsuhashi (President of APASL STC in Nagasaki)</td>
</tr>
<tr>
<td>9:30〜11:00</td>
<td>Session 1: Epidemiology and Risk Factors for HCC</td>
</tr>
<tr>
<td></td>
<td>Chairs: A. Kadir Dokmeci (Turkey), Osamu Yokosuka (Japan)</td>
</tr>
<tr>
<td>1.</td>
<td>Risk Factors for HCC in Patients with HCV after Anti-Viral Treatment</td>
</tr>
<tr>
<td></td>
<td>Yasuhiro Asahina (Japan)</td>
</tr>
<tr>
<td>2.</td>
<td>What We Know about the Host Genome and HCC in HCV Infection</td>
</tr>
<tr>
<td></td>
<td>Yoshiyuki Ueno (Japan)</td>
</tr>
<tr>
<td>3.</td>
<td>Hepatitis Action Plan and Changing Trend of Liver Disease in Japan</td>
</tr>
<tr>
<td></td>
<td>Tatsuya Kanto (Japan)</td>
</tr>
<tr>
<td>11:00〜11:30</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>11:30〜13:00</td>
<td>Luncheon Seminar 1</td>
</tr>
<tr>
<td></td>
<td>Chair: Takafumi Ichida (Japan)</td>
</tr>
<tr>
<td></td>
<td>Sponsored by Gilead Sciences K.K.</td>
</tr>
<tr>
<td>1.</td>
<td>Perspectives from Japanese Real-World (RW) Data - CHC and HCC</td>
</tr>
<tr>
<td></td>
<td>Tetsuo Takehara (Japan)</td>
</tr>
<tr>
<td>2.</td>
<td>Perspectives from Asia and the World - Extra Hepatic Manifestation</td>
</tr>
<tr>
<td></td>
<td>Mei-Hsuan Lee (Taiwan)</td>
</tr>
<tr>
<td>3.</td>
<td>Uncovering the Benefits of Hepatitis C Treatment and Beyond</td>
</tr>
<tr>
<td></td>
<td>Edward Gane (New Zealand)</td>
</tr>
<tr>
<td>13:00〜13:10</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>13:10〜14:40</td>
<td>Educational Symposium</td>
</tr>
<tr>
<td></td>
<td>Chair: Akio Ido (Japan)</td>
</tr>
<tr>
<td></td>
<td>Sponsored by Alexion Pharma</td>
</tr>
<tr>
<td>1.</td>
<td>Overview and Current Topics of Lysosomal Acid Lipase Deficiency (LAL-D)</td>
</tr>
<tr>
<td></td>
<td>Yoshikatsu Eto (Japan)</td>
</tr>
<tr>
<td>2.</td>
<td>LAL-D Hepatic Pathophysiology and Japanese Case with Hepatocellular Carcinoma</td>
</tr>
<tr>
<td></td>
<td>Koichi Shiraishi (Japan)</td>
</tr>
<tr>
<td>3.</td>
<td>Lipidology on Lysosomal Acid Lipase Deficiency</td>
</tr>
<tr>
<td></td>
<td>Masatsune Ogura (Japan)</td>
</tr>
<tr>
<td>14:40〜14:50</td>
<td>Coffee Break</td>
</tr>
</tbody>
</table>
14:50〜15:50  Session 2: HCC-1

Chair: Laurentius Lesmana  (Indonesia)

1. Immunotherapy for Hepatocellular Carcinoma
   Shuichi Kaneko  (Japan)

2. Intratumor Heterogeneity (ITH) of HCC
   Masao Omata  (Japan)

15:50〜16:00  Coffee Break

16:00〜17:00  Evening Seminar 1

Chair: Kazuhiko Nakao  (Japan)  Sponsored by AbbVie GK

1. Appropriate Selection of Direct-Acting Antivirals for Patients with Hepatitis C Virus Infection
   Yoichi Hiasa  (Japan)

2. Mechanisms Involved in the Development of NS5A-RAVs and NS5B-RAVs in Patients Receiving DAA Therapies
   Satoshi Mochida  (Japan)
April 11 (Tuesday) 2017

Room 1 (1st Floor "OHTORI A")

8:00〜9:00  Morning Seminar 1

Chair: Masao Omata (Japan)  Sponsored by Eisai Co., Ltd.

1. Treatment Strategies Taking into Account the Clinical Course Progressing to Advanced Hepatocellular Carcinoma
   Sadahisa Ogasawara (Japan)

2. Challenge to Advanced HCC by Hepatic Arterial Infusion Chemotherapy
   Shuntaro Obi (Japan)

9:00〜9:10  Coffee Break

9:10〜10:40  Session 3: HCV

Chair: Wan-Long Chuang (Taiwan)

1. New DAA Treatments for Hepatitis C Virus Infection
   Nobuyuki Enomoto (Japan)

2. APASL HCV Guidelines
   Tatsuo Kanda (Japan)

3. Post SVR Syndrome
   Hiroshi Yatsuhashi (Japan)

10:40〜10:50  Coffee Break

10:50〜11:50  Session 4: HBV

Chair: Jose Sollano (Philippines)

1. Prevention of HCC in HBV Infection in Korea
   Kwang-Hyub Han (Korea)

2. Prevention of HCC in HBV Infection
   Jia-Horng Kao (Taiwan)

11:50〜12:00  Coffee Break

12:00〜13:00  Luncheon Seminar 2

Chair: Kazuhiko Koike (Japan)  Sponsored by MSD K.K.

1. DAA Treatments in the Difficult-to-Treat Situations: Renal Failure and Hemodialysis Patients
   Naoya Sakamoto (Japan)

2. Recent Progress in Treatment Chronic Hepatitis C for Genotype 1
   Kazuaki Chayama (Japan)
13:00〜13:15 Coffee Break

13:15〜15:45 **Session 5: HCC-2**  
*Chairs: Wasim Jafri (Pakistan), George Lau (China)*

1. **HCC Genome and Therapeutic Strategy**  
   Naoya Kato (Japan)

2. **New HCC Diagnosis**  
   Masatoshi Kudo (Japan)

3. **Image-Guided Percutaneous Ablation for HCC**  
   Shuichiro Shiina (Japan)

4. **Conversion Therapy with Hepatic Arterial Infusion Chemotherapy Prolongs Overall Survival of Patients with Advanced Hepatocellular Carcinoma Involving Vascular Invasion**  
   Takuji Torimura (Japan)

5. **Asia-Pacific Clinical Practice Guideline on the Management of Hepatocellular Carcinoma: a 2016 Update**  
   Sadahisa Ogasawara (Japan)

15:45〜16:00 Coffee Break

16:00〜17:30 **Evening Seminar 2**  
*Chairs: Masashi Mizokami (Japan), Seung Kew Yoon (Korea)  Sponsored by Sysmex Corporation*

1. **Serum WFA+M2BP Levels for Evaluation of Early Stages of Liver Fibrosis and the Risk of HCC Development in Patients with Chronic Hepatitis B Virus Infection**  
   Xinxin Zhang (China)

2. **Direct Antiviral Agent Treatment of Chronic Hepatitis C Results in Rapid Regression of M2BPGi and Aspartate Aminotransferase-Platelet Ratio Index**  
   Jun-Qi Niu (China)

3. **Non-Invasive Predictors for HCC Development for Chronic Hepatitis C after Antiviral Therapy**  
   Ming Lung Yu (Taiwan)

4. **To be announced**  
   Yasuhiro Asahina (Japan)

5. **To be announced**  
   Kazumi Yamasaki (Japan)
April 11 (Tuesday) 2017

Room 2 (1st Floor "OHTORI B")

8:00〜9:00  Morning Seminar 2

Chair: Takashi Kumada (Japan)  Sponsored by Roche Diagnostics K.K.
1. Epidemiology of HBV and HCV Infections from the Viewpoint of Eradicating of Liver Cancer
   Junko Tanaka (Japan)
2. TLL1 Genetic Variants Associated with Development of Hepatocellular Carcinoma after Eradication of Hepatitis C Virus
   Yasuhito Tanaka (Japan)

12:00〜13:00  Luncheon Seminar 3

Chair: Namiki Izumi (Japan)  Sponsored by Otsuka Pharmaceutical Co., Ltd.
1. L-carnitine Treatment Improves Muscle Cramps and Impaired Brain Function in Liver Cirrhosis Patients
   Hiroyuki Nakanishi (Japan)
2. Effectiveness and Safety of Tolvaptan in Liver Cirrhosis Patients with Ascites
   Isao Sakaida (Japan)

13:00〜13:15  Coffee Break

13:15〜15:15  Session 6: LC (NASH)

Chairs: Shotaro Sakisaka (Japan), Barjesh C. Sharma (India)
1. Contribution of Hepatic Stellate Cells to Inflammation, Fibrosis and Cancer in Steatohepatitis
   Norifumi Kawada (Japan)
2. Oxidative Stress and Hepatocellular Carcinoma
   Keisuke Hino (Japan)
3. Fibrosis and HCC in NASH
   Hitoshi Yoshiji (Japan)
4. HCC in NASH; Any Difference from HCC of Other Etiologies?
   Etsuko Hashimoto (Japan)

15:20〜15:50  Special Lecture: HCC and Gene

Chair: Hiroshi Yatsuhashi (Japan)
1. Development of Non-Invasive Biomarker from Novel Gene Hunting in HCC: Diagnostic Biomarker and Therapeutic Target
   Seung Kew Yoon (Korea)
April 12 (Wednesday) 2017

**Room 1 (1st Floor "OHTORI A")**

**Morning Seminar 3**

8:00〜9:00

**Chair:** Kentaro Yoshioka (Japan)  
**Sponsored by Abbott Japan Co., Ltd.**

1. **Treatment of Chronic Hepatitis B and HCC**  
   Fumitaka Suzuki (Japan)

2. **Control of HBV in the Asian-Pacific Region**  
   Hiroshi Yotsuyanagi (Japan)

9:00〜9:10  
Coffee Break

9:10〜10:10

**Session 7: Lipid and HCV Lipid and HCC**

**Chairs:** Oidov Baatarkhuu (Mongolia), Naoya Kato (Japan)

1. **Molecular Mechanisms of HCV Membrane Replication Complex Formation**  
   Takaji Wakita (Japan)

2. **Mediators of Lipid Metabolism and Hepatocyte Apoptosis in NASH: How They Execute and Communicate**  
   Yuko Akazawa (Japan)

10:20〜10:30

**Closing Ceremony**

Hiroshi Yatsuhashi (President of APASL STC in Nagasaki)

---

**Room 2 (1st Floor "OHTORI B")**

**Morning Seminar 4**

8:00〜9:00

**Chair:** Hiroshi Yatsuhashi (Japan)  
**Sponsored by LSI Medience Corporation**

1. **Mass Spectrometry and Biomarker Analysis**  
   Kazuhiro Tanabe (Japan)

2. **Lipid Metabolic Disorders in HCV-Infected Liver: Metabolic Strategies for Antiviral Treatments**  
   Makoto Nakamuta (Japan)

9:10〜10:10

**Session 8: PBC**

**Chair:** Yasushi Matsuzaki (Japan)

1. **Biliary Epithelial Cells as Target for Primary Biliary Cholangitis**  
   Shinji Shimoda (Japan)

2. **Management of PBC**  
   Atsushi Tanaka (Japan)
Oral Free Papers

April 10 (Monday) 2017

Room 2 (1st Floor "OHTORI B")

9:50〜10:30 Oral Free Papers: PBC

Chair: Shinji Shimoda (Japan)

O-000 10147
Epidemiology, Clinical Features and Prognosis of Hepatocellular Carcinoma in Mongolia: A Multi-Center Study
Oidov Baatarkhuu (Mongolia)

O-001 10087
Dysfunctional DENND1B Induces T Cell Activation in PBC
Yoshimi Kaise (Japan)

O-002 10119
Ras Inhibitors Suppress the Inflammatory Cytokine Production in T Cells of Primary Biliary Cholangitis
Ryo Nakagawa (Japan)

O-003 10125
Asymptomatic and Symptomatic States are Independent Risk Factors Predicting PBC Long-Term Outcome
Satoru Joshita (Japan)

10:30〜11:20 Oral Free Papers: Fibrosis

Chair: Norifumi Kawada (Japan)

O-004 10038
Involvement of Decreased IGF Production in Hepatocarcinogenesis and Hepatic Fibrosis among Patients with HCV-related Chronic Liver Disease
Takashi Himoto (Japan)

O-005 10096
Serum Concentration of Galectin-9 Correlates to Liver Fibrosis
Koji Fujita (Japan)

O-006 10095
Virus-induced IFN-lambdas Cause Persistent Innate Immune Activation and Block IFN-alpha Signalling in HCV Infection
Pil Soo Sung (Korea)

O-007 10074
Role of Cytoglobin in the Development of Liver Fibrosis and Cancer in Human and in a Mouse Model of Non-Alcoholic Steatohepatitis
Le Thi Thanh Thuy (Japan)
O-008 10051
Comparison of US Scoring System with MR Elastography in the Evaluation of Liver Stiffness and Steatosis
Masaaki Shiina (Japan)

13:10〜13:50 Oral Free Papers: HBV
Chair: Yasuhito Tanaka (Japan)

O-009 10076
Hepatocellular Carcinoma (HCC) in the Japanese HBV Carrier Patients under 40
Hiroshi Yotsuyanagi (Japan)

O-010 10106
Development and Validation of a Simple Score to Select HBV-infected Patients Eligible for Antiviral Therapy in Sub-Saharan Africa
Yusuke Shimakawa (France)

O-011 10008
Androgen Receptor Affects the Expression of NKG2D Ligands in HBV-associated Human Hepatoma Cell Lines
Koji Takahashi (Japan)

O-012 10103
Hepatitis B Virus Genome Analysis in Patients of Hepatocellular Carcinoma and Asymptomatic Carriers from Northern, Southern and North East India
Premashis Kar (India)

13:50〜14:30 Oral Free Papers: Pathology
Chair: Masayoshi Kage (Japan)

O-013 10010
Pathological Characteristics of Patients Who Develop Hepatocellular Carcinoma after Sustained Virologic Response for Hepatitis C Virus Infection
Reiichiro Kondo (Japan)

O-014 10085
Changes in Clinical and Histological Parameters Predictive of Liver Fibrosis and/or HCC Development after Direct-Acting Antiviral Treatment for Chronic Hepatitis C
Masaru Enomoto (Japan)

O-015 10081
Abnormal Hepatocellular Organelles Remain to be Observed in Sustained Virological Response Patients
Haruyo Aoyagi (Japan)

O-016 10045
Risk Factors Associated with an Increase in Liver Stiffness in Patients with Type 2 Diabetes Mellitus: A Data-Mining Analysis
Takumi Kawaguchi (Japan)
14:30〜14:40  Coffee Break

14:40〜15:30  **Oral Free Papers: HCC Clinical-1**

*Chair: Keisuke Hino (Japan)*

**O-017 10118**  Consecutive Increment of Serum AFP Level is a Useful Surrogate Marker in Predicting HCC in Liver Cirrhosis Patients  
Si Hyun Bae (Korea)

**O-018 10041**  Hepatocellular Carcinoma Development in Hepatitis C Virus Patients who Achieved Sustained Viral Response by Interferon Therapy and Direct Anti-Viral Agents Therapy  
Yuko Nagaoki (Japan)

**O-019 10104**  Analysis of Developing HCC after Achieving SVR in Patients with DAAs Therapy for Hepatitis C  
Yasuhiko Nakao (Japan)

**O-020 10082**  Early Recurrence of Hepatocellular Carcinoma after Successful Therapy with Direct Acting Antiviral Agents for Chronic Hepatitis C: An Observational Study  
Mohamed Kohla (Egypt)

**O-021 10067**  Risk Factors for Recurrence of Hepatocellular Carcinoma after Radiofrequency Ablation: a Single Center Study  
Naoyuki Hino (Japan)

15:30〜16:20  **Oral Free Papers: HCC Clinical-2**

*Chair: Yutaka Sasaki (Japan)*

**O-022 10077**  Usefulness of Radiofrequency Ablation Training Program for Liver Tumors  
Shuichiro Shiina (Japan)

**O-023 10034**  Long-term Outcome of Liver Resection Versus Transplantation for Resectable Hepatocellular Carcinoma in a Region where Living Donation Accounts for a Main Source  
Pil Soo Sung (Korea)

**O-024 10084**  Impact of Radiofrequency Ablation-Induced Glisson’s Capsule-Associated Complications in Patients with Hepatocellular Carcinoma  
Toru Wakamatsu (Japan)

**O-025 10021**  Combination of Sorafenib with Transarterial Chemoembolization (TACE) Improves Survival as Compared to TACE Alone in Patients with Hepatocellular Carcinoma: A Metaanalysis of 17 Studies  
Ashish Kumar (India)
O-026 10039

Initial Results of Patients with Intermediate and Advanced Hepatocellular Carcinoma Treated with Selective Internal Radiation Therapy (SIRT)
Dao Duc Tien (Vietnam)

16:20〜17:00 Oral Free Papers: HCC Basic
Chair: Tsutomu Masaki (Japan)

O-027 10056

Regorafenib is a Promising Medicine for HCC Increasing Membrane-Bound MICA through ADAM 9 and 10 Suppression
Jun Arai (Japan)

O-028 10059

Genome-Wide Association Study-Derived Immunometabolic Strategies for Management of Hepatocellular Carcinoma
Kaku Goto (Japan)

O-029 10044

Epigenetic Regulation of CD133 and Chemosensitivity in Human HCC Cancer Stem Cells
Fanyin Meng (USA)

O-030 10048

Role of JNK1 in Promotion of Hepatocarcinogenesis by Obesity: a Molecular Target for HCC Chemoprevention
Evi Arifianti (Indonesia)
Poster Free Papers

April 10 (Monday) 2017 17:00〜18:30
Room 3 (1st Floor "ASUKA") P-001〜P-051

HBV

P-001 10006
Transient Elastography is Useful for the Evaluation of Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B Virus Infection Treated with Entecavir
Masaaki Shimada (Japan)

P-002 10042
Antiplatelet Therapy is Associated with Better Prognosis in Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma after Liver Resection
Po-Chun Chen (Taiwan)

P-003 10049
Investigate the Relevant Factors Associated with Low-Titer Hepatitis B Surface Antigen Carrier: A Community-Based Study
Cheng-Hung Chien (Taiwan)

P-004 10052
Influence of Hepatitis B Virus Genotypes on Innate Immune Response by Impairing Mitochondrial Antiviral Signaling Protein
Kenichi Morikawa (Japan)

P-005 10053
Hepatitis B Virus X Protein Modulates Host Restriction Factor via Interaction with DDB1
Takaaki Izumi (Japan)

P-006 10070
Fusion HBx from HBV Integrant Might Alter ER Stress Response and Contribute to Hepatocarcinogenesis
Ryosuke Muroyama (Japan)

P-007 10083
Association of Vitamin D-related Genetic Variations and Treatment Response to Pegylated Interferon in Thai Patients with Chronic Hepatitis B
Umaporn Limothai (Thailand)

P-008 10093
The Value of Using HBsAg and HBcrAg in Combination for the Assessment of HCC Risk
Yuichiro Suzuki (Japan)

P-009 10094
Activated gamma delta T Cells Concomitantly Exhibit Cytotoxicity and the Capacity for Viral Clearance in Patients with Acute Hepatitis B
Yuanyuan Li (China)

P-010 10100
MicroRNA 17-92 Induces Methylation of Hepatitis B Virus DNA in Human Hepatoma Cells
In Young Moon (Korea)
P-011  10101
TRAIL Receptor 1 (TRAIL-R1) Polymorphisms are Associated with Risk of Hepatitis B Related Hepatocellular Carcinoma
Apichaya Khlaiphuengsin (Thailand)

P-012  10110
The Characteristics and Outcomes of Patients Dropped Out Nucleotide Analogs Therapy
Shuichi Matsumoto (Japan)

P-013  10111
A Case of Hepatocellular Carcinoma Developed during Administration of Entecavir for De Novo Hepatitis B Reactivation
Yukiko Okamoto (Japan)

P-014  10121
Association of NTCP Polymorphisms with Clinical Outcome of Hepatitis B Infection in a Thai Cohort
Nongnaput Tuyapala (Thailand)

P-015  10124
Cross Sectional Assessment of Knowledge, Attitude and Practice (KAP) on Hepatitis B and Hepatitis C, Prevalence, and Risk Factors among High Risk Individuals
Peter Andrew C. Reyes (Philippines)

P-016  10128
Variation in the PreS/S Gene in HBV-Associated HCC Patients with the HLA-DPB1 0201 Allele
Yumi Hakozaki (Japan)

P-017  10130
Hepatitis B Core Related Antigen in Sera is the Surrogate Marker for HBV Covalently Closed Circular DNA Regardless Nucleic Acid Analogues Treatment
Takeshi Matsui (Japan)

P-018  10138
Usefulness of ALBI Grade in Prediction of Outcomes in Patients with Hepatitis B Related Hepatocellular Carcinoma
Kazuyuki Mizuno (Japan)

HCV-Post SVR

P-019  10007
Early Recurrence of HCC after Successful Treatment with DCV Plus ASV
Noboru Hirashima (Japan)

P-020  10016
Risk of Hepatocellular Carcinoma after Sustained Virologic Response by Interferon-Free Treatment Compared with Interferon-Based Treatment for Chronic Hepatitis C
Naoto Kawabe (Japan)

P-021  10050
Efficacy and HCC Development after DAAs Therapy for Patients with Chronic Hepatitis C
Akitoshi Douhara (Japan)
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-022</td>
<td>Evaluation of Anti Carcinogenic Effect after Antiviral Therapy (PEGRIB and DAA) for Type C Chronic Liver Disease Patients</td>
<td>Koichi Takaguchi (Japan)</td>
</tr>
<tr>
<td>P-023</td>
<td>Recurrence Pattern in Patients who Underwent Antiviral Therapy after Curative Treatment of HCV Related Hepatocellular Carcinoma</td>
<td>Yutaka Yasui (Japan)</td>
</tr>
<tr>
<td>P-024</td>
<td>Development of Hepatocellular Carcinoma after Treatment with Direct Acting Antivirals in Hepatitis C Virus-related Chronic Liver Diseases</td>
<td>Kyo Sasaki (Japan)</td>
</tr>
<tr>
<td>P-025</td>
<td>Assessment with Characteristics and Risk of Developing Hepatocellular Carcinoma after Eradication of Hepatitis C Virus by Interferon-Free Therapy</td>
<td>Etsuko Iio (Japan)</td>
</tr>
<tr>
<td>P-026</td>
<td>Two Cases of Rapid-Growing Hepatocellular Carcinoma after Direct Acting Anti-Viral Treatment of Hepatitis C Virus Infection</td>
<td>Toshihiro Kawaguchi (Japan)</td>
</tr>
<tr>
<td>P-027</td>
<td>The Preventive Effect for Recurrence by Interferon-Free DAA Treatment in the Patients with HCC Curative Treatment</td>
<td>Masakuni Tateyama (Japan)</td>
</tr>
<tr>
<td>P-028</td>
<td>Development of Hepatocellular Carcinoma in the Patient Occurred Newly just after Sustained Virological Response to Ledipasvir/Sofosbuvir against Chronic Hepatitis C: A Case Report</td>
<td>Daiki Ozono (Japan)</td>
</tr>
<tr>
<td>P-029</td>
<td>The Features of Hepatocellular Carcinoma Following Treatment with Direct-Acting Antivirals for Hepatitis C</td>
<td>Seiichi Mawaturi (Japan)</td>
</tr>
<tr>
<td>P-030</td>
<td>The Incidence of Hepatocellular Carcinoma after Daclatasvir plus Asunaprevir Therapy in HCV-1b Hepatitis who Achieved Sustained Virologic Response</td>
<td>Mitsuaki Sato (Japan)</td>
</tr>
<tr>
<td>P-031</td>
<td>Hepatocellular Carcinoma Occurred after Exclusion of Hepatitis C Virus with Interferon-Free Treatment</td>
<td>Hideo Kunimoto (Japan)</td>
</tr>
</tbody>
</table>
P-032  10133
Genetics Variants and Serum Levels of MHC Class I Chain-Related A in Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis C Patients Post Antiviral Treatment
Ming-Lung Yu (Taiwan)

P-033  10137
A Case of Diffuse Hepatocellular Carcinoma Diagnosed after DAA Treatment
Takeaki Satoh (Japan)

P-034  10141
Characteristics and Prognosis of Patients with Hepatocellular Carcinoma that Developed after Hepatitis-C Virus Eradication
Tatsuya Minami (Japan)

P-035  10146
Analysis of Hepatocellular Carcinoma after Achievement of Sustained Viral Response with Daclatasvir and Asunaprevir for Hepatitis C Virus Infection
Hiroshi Ida (Japan)

HCV
P-036  10069
Analysis of the Relationship between Alcohol Drinking and HCV-Related Hepatocellular Carcinoma by Estimation of Lifetime Total Alcohol Intake
Masanori Tokoro (Japan)

P-037  10023
Comparison of the Anti-HCV Effects of IFN-Based Therapy and IFN-Free Therapy for Patients after Curative HCC Treatment
Akihiro Tamori (Japan)

P-038  10026
Diversity of the Association of Serum Levels and Genetic Variants of MHC Class I Polypeptide-Related Chain A with Liver Fibrosis in Chronic Hepatitis C
Jee-Fu Huang (Taiwan)

P-039  10027
Effectiveness of Sofosbuvir-Based Regimens for Japanese Patients with HCV Genotype 1 or 2 Infection: Real Life Experience from a Multicenter Cohort
Eiichi Ogawa (Japan)

P-040  10072
Polymorphisms in MICA, but not in DEPDC5, HCP5 or PNPLA3, are Associated with Chronic Hepatitis C-Related Hepatocellular Carcinoma
Hoang Hai (Japan)

P-041  10117
Liver Dysfunction Caused by Daclatasvir and Asunaprevir Combination Therapy-its Influence on the SVR Rate and the Association with the Drug-Metabolizing Enzyme Polymorphisms
Natsuhiko Kuratomi (Japan)
<table>
<thead>
<tr>
<th>Session</th>
<th>Paper ID</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-042</td>
<td>10129</td>
</tr>
<tr>
<td>P-043</td>
<td>10134</td>
</tr>
<tr>
<td>P-044</td>
<td>10142</td>
</tr>
<tr>
<td>P-045</td>
<td>10143</td>
</tr>
<tr>
<td>P-046</td>
<td>10144</td>
</tr>
<tr>
<td>P-047</td>
<td>10002</td>
</tr>
<tr>
<td>P-048</td>
<td>10017</td>
</tr>
<tr>
<td>P-049</td>
<td>10035</td>
</tr>
<tr>
<td>P-050</td>
<td>10105</td>
</tr>
<tr>
<td>P-051</td>
<td>10127</td>
</tr>
</tbody>
</table>

**Gene Expression Profile on Hepatocellular Carcinoma Cells with Different Intracellular Hepatitis C Viral Load**  
Chia-Yen Dai (Taiwan)

**Hepatitis C Virus Infection: A Case Series**  
Angelo Jonathan D. Cruz (Philippines)

**HCV Management in Mongolia**  
Naranzul Nyamsuren (Mongolia)

**Ledipasvir and Sofosbuvir Treatment Results for Hepatitis C Genotype 1b Patients in Mongolia**  
Oidov Baatarkhuu (Mongolia)

**The Efficacy of Peginterferon plus Ribavirin in Patients with Genotype 1 Chronic Hepatitis C in Mongolia**  
Uugantsetseg G (Mongolia)

**Impact of Vitamin D Replacement on Liver Enzymes in Non-Alcoholic Fatty Liver Disease Patients**  
Suparuedee Boonyagard (Thailand)

**Combination Treatment of Dipeptidyl Peptidase IV Inhibitor (Sitagliptin) and Angiotensin-II Type 1 Receptor Blocker (Losartan) Suppresses Progression in a Nondiabetic Rat Model of Steatohepatitis**  
Shinya Sato (Japan)

**The Role of PPARβ/δ in CD11b+ Resident Liver Macrophages on Liver Steatosis**  
Jiapeng K. Chen (Singapore)

**Characteristics of Elderly Patients with Nonalcoholic Fatty Liver Disease**  
Maki Tobari (Japan)

**The Association between Serum Levels of Sptlc3 and the Clinical Features of Patients with NAFLD**  
Sho Ijyuin (Japan)
HCC-Basic

P-052  10012

Antitumor Effect of Carnosic Acid on Human Hepatoma Cell Lines
Ting Wang (Japan)

P-053  10013

Antitumoral Effect of SGLT2 Inhibitor against Human Liver Cancer
Kosuke Kaji (Japan)

P-054  10015

Dual Therapy with Acyclic Retinoid and Angiotensin-II Receptor1 Blocker Ameliorates Chemically Induced Hepatocarcinogenesis in Diabetic OLETF Rats
Norihisa Nishimura (Japan)

P-055  10018

Angiotensin II Receptor Blocker Attenuates Human Cholangiocarcinoma through Inhibition of the Hippo-YAP Signaling Pathway
Soichiro Saikawa (Japan)

P-056  10019

Preventive Effects of the Sodium Glucose Cotransporter 2 Inhibitor Tofogliflozin on Liver Tumorigenesis in Obese Mice
Yohei Shirakami (Japan)

P-057  10020

DPP-4 Inhibitor Suppresses the Progression of Hepatocellular Carcinoma through Activation of Chemotaxis of NK Cells in Mice
Sohji Nishina (Japan)

P-058  10029

The Epigenetic Roles of Protein Kinase R in Hepatocellular Carcinoma with Hepatitis C Virus Infection, and Possibility of PKR Inhibitor as a Therapeutic Target
Takao Watanabe (Japan)

P-059  10031

Down-Regulated Expression of ANP32B Has Anti-Apoptotic Function in Hepatocellular Carcinoma
Yoshinori Ohno (Japan)

P-060  10054

The Role of Heme Oxygenase-1 in Liver Cancer Development and Progression
Xiaowen Mao (Hong Kong)

P-061  10057

Systems Approach to Characterize the Metabolism of Liver Cancer Stem Cells Expressing CD133
Seung Kew Yoon (Korea)

P-062  10058

ELK3 Promotes the Migration and Invasion of Liver Cancer Stem Cells by Targeting HIF-1α
Seung Kew Yoon (Korea)
Histone Deacetylase-Targeted Exploration for Expression Inducer of MHC Class I Polypeptide-Related Sequence A
Sayaka Ito (Japan)

Iron Chelator Suppresses Hepatocarcinogenesis through Mitophagy Induction in STAM Mice
Yuichi Hara (Japan)

Rapid Progression of Hepatocellular Carcinoma in Neuropeptide Y Knockout Mice
Ayaka Kinoshita (Japan)

Hepatoprotective Effect of Isotoma longiflora (L) Presl. Leaves Extract on Carbon Tetrachloride-induced Hepatotoxicity in Mice
Enikarmila Asni (Indonesia)

Glycolysis Inhibitors Enhance Inhibition of Hepatoma Cell Growth
Jae Hee Choi (Korea)

Effect of the Anti-diabetic Drug Metformin in Hepatocellular Carcinoma in Vitro and in Vivo
Asahiro Morishita (Japan)

Screening, Identification Antivascular Biomarkers of Hepatocellular Carcinoma
Kun Yan (China)

Transarterial Infusion of Epirubicin and Cisplatin Combined with Systemic Infusion of 5-Fluorouracil Versus Transcatheter Arterial Chemoembolization Using Doxorubicin for Unresectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis
Sung Won Lee (Korea)

Does Obesity with Visceral Fat Influence Recurrence and Survival in Patients with Hepatocellular Carcinoma?
Atsushi Hiraoka (Japan)

Comparison between Percutaneous Radiofrequency Therapy and Stereotactic Body Radiation Therapy (SBRT) for Hepatocellular Carcinoma: Early Experience of CyberKnife, SBRT System, in Our Hospital
Yasuhide Motoyoshi (Japan)

Long-term Survival Result of Patients with Hepatocellular Carcinoma Treated with Trans-Arterial Chemoembolization Using Drug-Loaded Microspheres
Thai Doan Ky (Vietnam)
P-074 10037
Efficacy of Sorafenib for Hepatocellular Carcinoma and Impact on Prognosis
Taketo Nishina (Japan)

P-075 10040
Treatment of Hepatocellular Carcinoma by Radiofrequency Ablation Using Cool-tip RF Electrode: Prospective Results on 82 Patients
Nguyen Thi Thu Huyen (Vietnam)

P-076 10043
Factors Associated with the Prognosis of Patients with Non-Hepatitis B Virus-, Non-Hepatitis C Virus-Related Hepatocellular Carcinoma
Yu Noda (Japan)

P-077 10055
Non-Hypervascular Hepatobiliary Phase Hypointense Nodules on Gd-EOB-DTPA-Enhanced MRI as a Risk Factor for Intrahepatic Distant Recurrence of Hepatocellular Carcinoma after Radiofrequency Ablation
Masanori Inoue (Japan)

P-078 10063
Analysis of Factors for Respiratory Depression and Severe Body Movement in Radiofrequency Ablation under Deep Sedation
Koki Sato (Japan)

P-079 10064
The Change of Serum Wisteria Floribunda Agglutinin-Positive Mac-2 Binding Protein (M2BPGi) is a Predictive Marker of the Recurrence of Hepatocellular Carcinoma in Patients after RFA
Masato Nakai (Japan)

P-080 10075
Survival Outcome of Resectable HCC in Young Adult; A Single Center Experience
Sunhawit Junrungsee (Thailand)

P-081 10080
Clinicopathological Characteristics of Non-B Non-C Hepatocellular Carcinoma without Past HBV Infection
Takefumi Kimura (Japan)

P-082 10089
Hepatectomy is Beneficial to Intermediate and Advanced Hepatocellular Carcinoma: A Cohort Study in Taiwan
Chi-Ling Chen (Taiwan)

P-083 10098
Sarcopenia as Prognostic Factor in Hepatocellular Carcinoma
Benjamin T. Castro Jr (Philippines)

P-084 10109
Three Cases Report of the Sorafenib Treatment for Hepatocellular Carcinoma who are Advanced Age, about an Effect and Tolerability
Yasunari Kaneyama (Japan)
P-085 10114
Survival Benefit of Liver Resection for Hepatocellular Carcinoma with Hepatic Vascular Invasion
Yasuhiro Nakayama (Japan)

P-086 10116
Decreased EGFL6 Expression is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma
Hui Ting Hsu (Taiwan)

P-087 10122
Prognostic Role of Circulating miR-221 in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization
Piyawan Chailapakul (Thailand)

P-088 10123
Natural History of Untreated Hepatocellular Carcinoma in Thai Patients: A Single-Center Experience
Siwaporn Chainuvati (Thailand)

P-089 10126
Effectiveness of Drug-Eluting Bead-Transarterial Chemo-Embolization in Intermediate Stage of Hepatocellular Carcinoma
Akihiro Deguchi (Japan)

P-090 10131
Pure Laparoscopic Right Hepatectomy for HCC with Umbilical Zigzag Inciseon
Toshio Shikano (Japan)

P-092 10139
Conversion Therapy with Hepatic Arterial Infusion Chemotherapy for Long-Term Prognosis in Patients with Advanced Hepatocellular Carcinoma Involving Vascular Invasion
Hiroaki Nagamatsu (Japan)

LC
P-095 10014
The Relationship between Malnutrition Universal Screen Tool (MUST) Scores and Liver Function Indexes in Cirrhotic Patients
Ying-Chen Hung (Taiwan)

P-096 10022
Effect of Raloxifene on Rats with Biliary Cirrhosis
Ching-Chih Chang (Taiwan)

P-097 10025
The Mortality of Cirrhotic Patients with Heart Failure
Yen-Chun Chen (Taiwan)

P-098 10033
Food Consumption Behavior in Elderly Cirrhotic Patients
Fang-Yen Kuo (Taiwan)

P-099 10092
A Patient with Liver Cirrhosis Confirmed Reduction in Activity of Lysosomal Acid Lipase (LAL)
Yuki Kugiyama (Japan)
P-100 10140
Efficacy of Tolvaptan for Refractory Ascites in Cirrhotic Patients with Hepatocellular Carcinoma
Motonori Shimizu (Japan)

P-101 10145
Hepatopulmonary Syndrome is Closely Related with Bacterial Translocation in Cirrhosis
Moon Young Kim (Korea)

P-102 10148
Adverse Outcomes after Non-Hepatic Surgery in Patients with Liver Cirrhosis: A Nationwide Study
Chien-Chang Liao (Taiwan)

P-103 10148
N Butyl 2 Cyanoacrylate Therapy of Bleeding Gastric Fundal Varices: The Experience of Tertiary Care Hospitals
Farhan Haleem (Pakistan)

P-104 10149
The Role of Partial Splenic Artery Embolization in Cirrhotic Patients with Hypersplenism
Ayman N. Menessy (Egypt)

P-105 10150
Difference of Thrombocytopenia between Alcoholic and Viral LC
Seulki Kim (Korea)

P-106 10151
Fontan-Associated Liver Disease: Diagnosis by Elastography and Laparoscopic Liver Biopsy
Yohei Koizumi (Japan)

P-107 10152
The Significance of the Assessment of Liver Stiffness at Medical Health Checkup
Taro Shibuki (Japan)

P-108 10153
Comparative Study of Non-Invasive Liver Fibrosis Assessment Methods between Patients with and without Hepatocellular Carcinoma
Akemi Tsutsui (Japan)

Others
P-109 10155
IgG4 Sclerosing Cholangitis and Post Infantile Giant Cell Hepatitis: A Case Report of an Extraordinary Copresentation
Maha Elabaawy (Egypt)

P-110 10156
Case Report: A Case of Acute Liver Failure in A 52-year Old Female Caused by Autoimmune Hepatitis (AIH) Masquerading as Non-Alcoholic Fatty Liver Disease (NAFLD)
Chuck Eduard B. Galon (Philippines)

P-111 10157
Utilization of Computerized Database System to Facilitate the Efficiency of Case Management for the Chronic Hepatitis B and Hepatitis C Patients in Liver Clinic
I Ling Liu (Taiwan)
<table>
<thead>
<tr>
<th>No.</th>
<th>Code</th>
<th>Title</th>
</tr>
</thead>
</table>
| P-112 | 10079 | Epidemiological Study on Age-Sex Stratified Prevalence of HBV, HCV and HAV in 1200 Random Samples from General Population and Employees  
Chikako Yamamoto (Japan) |
| P-113 | 10004 | Fasciola Liver Abscess: An Unrecognized and Fatal but Curable Disease  
Siripa Puasripun (Thailand) |
| P-114 | 10115 | Mixed Pyogenic and Tuberculous Liver Abscess in 67 Year Old Female  
Francis Rodencio B. Mantilla (Philippines) |
| P-115 | 10001 | Comparing Response Rate between High Dose and Standard Dose Hepatitis B Vaccination in Cirrhotic Patients  
Petcharee Polmanee (Thailand) |
| P-116 | 10088 | Posttransplant Diabetes Mellitus after Liver Transplantation: Risk Factors for Persistence  
Yang Won Nah (Korea) |
| P-117 | 10149 | The Effect of Acute Pancreatitis on the Mortality of Patients with Liver Cirrhosis  
Tsung Hsing Hung (Taiwan) |
| P-118 | 10150 | The Close Linkage between the Elasticity Modulus Measured by 2D Shear Wave Elastography and the Presence of Hepatocellular Carcinoma in Patients with a SVR to Interferon for CH-C  
Yasuharu Imai (Japan) |
| P-119 | 10151 | Interventional Oncology (IVO) Suite at Juntendo University, New RFA Treatment Room  
Masashi Takawa (Japan) |
| P-120 | 10152 | Lusutrombopag in Radiofrequency Ablation  
Ryo Kanazawa (Japan) |